The purpose of this study is to evaluate the efficacy and safety (including evaluating side
effects) of combination of olaparib and abiraterone versus placebo and abiraterone in
patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no
prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant
prostate cancer (mCRPC) stage.
PROpel is a phase III study evaluating the efficacy, safety, and tolerability of olaparib
versus placebo when given in addition to abiraterone to patients with metastatic
castration-resistant prostate cancer (mCRPC) who have not received prior chemotherapy or new
hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC)
Approximately 720 patients globally were planned to be randomized in PROpel in a 1:1 ratio to
treatment with either olaparib and abiraterone or placebo and abiraterone. Enrolment had
completed with a total of 796 patients randomised. Following the completion of global
enrolment, the China cohort will randomise approximately 108 additional patients at sites in
China, also in a 1:1 ratio.
Patients will receive oral treatment with olaparib 300 mg twice daily + abiraterone 1000 mg
once daily or placebo twice daily + abiraterone 1000 mg once daily. Patients in both
treatment groups will also receive either prednisone or prednisolone 5 mg twice daily.
1. Capable of giving signed informed consent, which includes compliance with the
requirements and restrictions listed in the informed consent form and in the study
2. Provision of signed and dated, written informed consent form prior to any mandatory
study specific procedures, sampling, and analyses.
3. For inclusion in i) the optional exploratory genetic research and ii) the optional
biomarker research, patients must fulfill the following criteria:
- Provision of informed consent for genetic research prior to collection of sample.
- Provision of informed consent for biomarker research prior to collection of
If a patient declines to participate in the optional exploratory genetic research or
the optional biomarker research, there will be no penalty or loss of benefit to the
patient. The patient will not be excluded from other aspects of the study.
4. Patients must be ≥18 years of age (or ≥19 years of age in South Korea) at the time of
signing the informed consent form. For patients enrolled in Japan who are <20 years of
age, written informed consent should be obtained from the patient and from his legally
5. Histologically or cytologically confirmed prostate adenocarcinoma.
6. Metastatic status defined as at least 1 documented metastatic lesion on either a bone
scan or a computed tomography(CT)/ magnetic resonance imaging (MRI) scan.
7. First-line metastatic castration-resistant prostate cancer (mCRPC).
8. Ongoing androgen deprivation with gonadotropin-releasing hormone analogue or bilateral
orchiectomy, with serum testosterone <50 nanograms per decilitre (ng/dL) (<2.0
nanomoles per litre (nmol/L)) within 28 days before randomisation. Patients receiving
androgen deprivation therapy (ADT) at study entry should continue to do so throughout
9. Candidate for abiraterone therapy with documented evidence of progressive disease.
10. Patients must have normal organ and bone marrow function measured within 28 days prior
to administration of study treatment.
11. Eastern Cooperative Oncology Group (ECOG) performance status 0-1, with no
deterioration over the previous 2 weeks.
12. The participant has, in the opinion of the investigator, a life expectancy of at least
13. Prior to randomisation, sites must confirm availability of either an archival formalin
fixed, paraffin embedded (FFPE) tumour tissue sample, or a new biopsy taken during the
screening window, which meets the minimum pathology and sample requirements in order
to enable homologous recombination repair (HRR) status subgroup analysis of the
primary endpoint radiographic progression-free survival (rPFS). If there is not
written confirmation of the availability of tumour tissue prior to randomisation, the
patient is not eligible for the study.
14. Male patients must use a condom during treatment and for 3 months after the last dose
of olaparib+abiraterone when having sexual intercourse with a pregnant woman or with a
woman of childbearing potential. Female partners of male patients should also use a
highly effective form of contraception if they are of childbearing potential.
1. Has a known additional malignancy that has had progression or has required active
treatment in the last 5 years.
2. Patients with myelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML) or with
features suggestive of yelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML).
3. Clinically significant cardiovascular disease Association Class II-IV heart failure or
cardiac ejection fraction measurement of <50% during screening as assessed by
echocardiography or multigated acquisition scan.
4. Planned or scheduled cardiac surgery or percutaneous coronary intervention procedure.
5. Prior revascularisation procedure (significant coronary, carotid, or peripheral artery
6. Uncontrolled hypertension (systolic blood pressure (BP) ≥160 millimeters of mercury
(mmHg) or diastolic blood pressure (BP) ≥95 millimeters of mercury (mmHg)).
7. History of uncontrolled pituitary or adrenal dysfunction.
8. Active infection or other medical condition that would make prednisone/prednisolone
9. Any chronic medical condition requiring a systemic dose of corticosteroid >10
milligrams (mg) prednisone/prednisolone per day.
10. Patients who are considered a poor medical risk due to a serious, uncontrolled medical
disorder, non-malignant systemic disease or active, uncontrolled infection.
11. Persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAEs] grade
>2) caused by previous cancer therapy, excluding alopecia.
12. Patients with brain metastases. A scan to confirm the absence of brain metastases is
13. Patients with spinal cord compression are excluded unless they are considered to have
received definitive treatment for this and have evidence of clinically stable disease
for 4 weeks.
14. Patients who are unevaluable for both bone and soft tissue progression
15. Patients who are unable to swallow orally administered medication and patients with
gastrointestinal disorders likely to interfere with absorption of the study
16. Immunocompromised patients
17. Patients with known active hepatitis infection (ie, hepatitis B or C).
18. Any previous treatment with Polyadenosine 5'diphosphoribose [poly (ADP ribose)]
polymerase (PARP) inhibitor, including olaparib.
19. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative
reasons) within 3 weeks prior to study treatment. Patients who receive palliative
radiotherapy need to stop radiotherapy 1 week before randomisation.
20. Any previous exposure to a Cytochrome P450 (CYP) 17 (17α-hydroxylase/C17,20-lyase)
inhibitor (eg, abiraterone, orteronel).
21. Concomitant use of known strong Cytochrome P450 (CYP) 3A inhibitors (eg, itraconazole,
telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or
cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate
CYP3A inhibitors (eg, ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil).
The required washout period prior to starting study treatment is 2 weeks.
22. Concomitant use of known strong Cytochrome P450 (CYP) 3A inducers (eg, phenobarbital,
enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine
or St John's wort) or moderate Cytochrome P450 (CYP) 3A inducers (eg, bosentan,
efavirenz or modafinil). The required period prior to starting study treatment is 5
weeks for phenobarbital and enzalutamide and 3 weeks for other agents.
23. Major surgery within 2 weeks of starting study treatment and patients must have
recovered from any effects of any major surgery.
24. Previous allogenic bone marrow transplant or double umbilical cord blood
25. Participation in another clinical study with an investigational product or
investigational medical devices within 1 month of randomisation.
26. History of hypersensitivity to olaparib or abiraterone, any of the excipients of
olaparib or abiraterone, or drugs with a similar chemical structure or class to
olaparib or abiraterone.
27. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
and Merck staff and/or staff at the study site).
28. Judgment by the investigator that the patient should not participate in the study if
the patient is unlikely to comply with study procedures, restrictions and
29. Previous randomisation in the present study.